PEAK6 Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PEAK6 Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,003	Closed	-$1.18M	–	4929
2023 Q4	$1.18M	Buy	+20,003	New	+$1.12M	﹤0.01%	1947
2023 Q3	–	Sell	-4,178	Closed	-$151K	–	4708
2023 Q2	$151K	Sell	4,178 -2,322	-36%	-$95.7K	﹤0.01%	3031
2023 Q1	$242K	Sell	6,500 -7,207	-53%	-$324K	﹤0.01%	2969
2022 Q4	$621K	Sell	13,707 -4,855	-26%	-$314K	﹤0.01%	2327
2022 Q3	$1.3M	Sell	18,562 -16,194	-47%	-$1.2M	0.01%	1947
2022 Q2	$2.2M	Buy	34,756 +24,350	+234%	+$1.55M	﹤0.01%	2223
2022 Q1	$856K	Buy	+10,406	New	+$1.06M	﹤0.01%	2641

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PEAK6 Investments's MRTX Position: Q1 2024 in Review

PEAK6 Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 20,003 shares — an estimated $1.18M sold.

PEAK6 Investments first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $2.2M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

PEAK6 Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
PEAK6 Investments sold 20,003 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.18M.
PEAK6 Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
PEAK6 Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $2.2M in Q2 2022.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.